<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6083217\results\search\tropicalVirus\results.xml">
  <result pre="pmcid: 6083217 doi: 10.3389/fmicb.2018.01797 : Microbiology: Mini Review Role of" exact="Zika" post="Virus prM Protein in Viral Pathogenicity and Use in"/>
  <result pre="permitted which does not comply with these terms. Abstract Recent" exact="Zika" post="virus (ZIKV) epidemics necessitate the urgent development of effective"/>
  <result pre="vaccines, which can be accelerated by an enhanced understanding of" exact="ZIKV" post="biology. One of the ZIKV structural proteins, precursor membrane"/>
  <result pre="by an enhanced understanding of ZIKV biology. One of the" exact="ZIKV" post="structural proteins, precursor membrane (prM), plays an important role"/>
  <result pre="be implicated in the neurovirulence of ZIKV. Most vaccines targeting" exact="ZIKV" post="include prM as the immunogen. Here, we review progress"/>
  <result pre="the immunogen. Here, we review progress in our understanding of" exact="ZIKV" post="prM protein and its application in ZIKV vaccine development."/>
  <result pre="our understanding of ZIKV prM protein and its application in" exact="ZIKV" post="vaccine development. ZIKV prM viral pathogenicity vaccine epidemic Funding"/>
  <result pre="ZIKV prM protein and its application in ZIKV vaccine development." exact="ZIKV" post="prM viral pathogenicity vaccine epidemic Funding Ministry of Science"/>
  <result pre="Technology, Taiwan10.13039/501100004663MOST 105-2628-B-039-006-MY3 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Zika" post="virus (ZIKV) was first isolated in 1947 from a"/>
  <result pre="isolated in 1947 from a rhesus monkey taken from the" exact="Zika" post="Forest in Uganda (Dick et al., 1952). Prior to"/>
  <result pre="Uganda (Dick et al., 1952). Prior to the emergence of" exact="ZIKV" post="epidemics, there had been only a few reported cases"/>
  <result pre="epidemics, there had been only a few reported cases of" exact="ZIKV" post="infection in humans in Africa and Asia, most of"/>
  <result pre="al., 1981; Adekolu-John and Fagbami, 1983). A major outbreak of" exact="ZIKV" post="was reported on Yap Island in 2007, which infected"/>
  <result pre="2014 and 2015, respectively (ECDC, 2014; Hennessey et al., 2016)." exact="Zika" post="virus outbreaks from 2015 onward have been of major"/>
  <result pre="declared an urgent need to fully understand the lifecycle of" exact="ZIKV" post="and its infection dynamics in order to develop effective"/>
  <result pre="vaccines and therapeutic targets to prevent future outbreaks (WHO, 2016)." exact="Zika" post="virus is mainly transmitted to humans through mosquito-borne vectors"/>
  <result pre="also been reported (Song et al., 2017). Phylogenetic analyses of" exact="ZIKV" post="identified African and Asian lineages, with the Asian lineage"/>
  <result pre="now? Secondly, despite being initially isolated from Africa, why do" exact="ZIKV" post="strains of the African lineage not cause epidemics? Thirdly,"/>
  <result pre="in neural cells than African strains. A phylogenetic analysis of" exact="ZIKV" post="strains responsible for recent epidemics in Asia has further"/>
  <result pre="giving rise to several biological phenotypes (Zhu et al., 2016)." exact="Zika" post="virus has biological similarities to other flaviviruses, such as"/>
  <result pre="Zika virus has biological similarities to other flaviviruses, such as" exact="West Nile" post="virus, Japanese encephalitis virus (JEV) and dengue virus. ZIKV"/>
  <result pre="West Nile virus, Japanese encephalitis virus (JEV) and dengue virus." exact="ZIKV" post="has an approximately 11 kb positive-stranded RNA genome, with"/>
  <result pre="ingress and egress of host cells (Li et al., 2008)." exact="ZIKV" post="virion assembly involves: (i) prM interaction with E protein"/>
  <result pre="homodimers and facilitating virion maturation. Recent studies have revealed that" exact="ZIKV" post="has a similar structure to other known flaviviruses (Kostyuchenko"/>
  <result pre="the function of prM during the viral lifecycle may incapacitate" exact="ZIKV" post="infectivity and pathogenicity. ZIKV prM and E proteins are"/>
  <result pre="during the viral lifecycle may incapacitate ZIKV infectivity and pathogenicity." exact="ZIKV" post="prM and E proteins are being used as antibody-activating"/>
  <result pre="are being used as antibody-activating epitopes in most of the" exact="ZIKV" post="vaccines currently undergoing clinical trials (WHO, 2018). This short"/>
  <result pre="highlight recent advances in our understanding of the role of" exact="ZIKV" post="prM protein in virus pathogenicity and its use in"/>
  <result pre="pathogenicity and its use in vaccine development. Pre-Epidemic and Epidemic" exact="ZIKV" post="Strain prM Proteins and Their Pathogenicities Zika virus has"/>
  <result pre="Pre-Epidemic and Epidemic ZIKV Strain prM Proteins and Their Pathogenicities" exact="Zika" post="virus has been categorized into pre-epidemic and epidemic strains"/>
  <result pre="et al., 1981; Adekolu-John and Fagbami, 1983). Epidemic strains represent" exact="ZIKV" post="isolates linked to human infections from outbreaks on Yap"/>
  <result pre="2017; Bos et al., 2018). A recent genomic analysis of" exact="ZIKV" post="strains revealed two amino acid substitutions in ZIKV prM"/>
  <result pre="analysis of ZIKV strains revealed two amino acid substitutions in" exact="ZIKV" post="prM protein isolated from strains contributing to epidemics in"/>
  <result pre="sequenced epidemic strains, nine amino acid substitutions were identified in" exact="ZIKV" post="prM protein (Zhu et al., 2016). Another study found"/>
  <result pre="study found 10 amino acid substitutions between pre-epidemic and epidemic" exact="ZIKV" post="prM proteins (Bos et al., 2018) (Table 1). These"/>
  <result pre="(Table 1). These genomic variations might have been driven by" exact="ZIKV" post="adopting an urban-based transmission cycle targeting humans as hosts"/>
  <result pre="genome to enable it to maintain its replication efficiency. Epidemic" exact="ZIKV" post="strains, including those associated with neurovirulence, have been shown"/>
  <result pre="have driven the amino acid substitutions and protein evolution of" exact="ZIKV" post="prM proteins (Ramaiah et al., 2017). Table 1 Summary"/>
  <result pre="prM proteins (Ramaiah et al., 2017). Table 1 Summary of" exact="ZIKV" post="prM amino acid substitutions. Pre-epidemic amino acid residue Epidemic"/>
  <result pre="acid residue Epidemic amino acid residue Amino acid position in" exact="ZIKV" post="prM Amino acid position in ZIKV polyprotein Reference I"/>
  <result pre="Amino acid position in ZIKV prM Amino acid position in" exact="ZIKV" post="polyprotein Reference I V 3 161 Bos et al.,"/>
  <result pre="al. (2017) studied the effects of the commonly observed epidemic" exact="ZIKV" post="amino acid substitutions in C, prM, E, NS1, and"/>
  <result pre="examined, a serine to asparagine amino acid substitution (S139N) of" exact="ZIKV" post="prM protein, which is observed in most human epidemic"/>
  <result pre="contributed to the recently observed congenital birth defects associated with" exact="ZIKV" post="outbreaks in Brazil (Krauer et al., 2017). The contributions"/>
  <result pre="et al., 2017). The contributions of other prM substitutions to" exact="ZIKV" post="neurovirulence remain to be studied in depth as Yuan"/>
  <result pre="completely prevent it. Another study suggested that the highly thermostable" exact="ZIKV" post="E protein, unlike DENV E protein, may also be"/>
  <result pre="study suggested that the highly thermostable ZIKV E protein, unlike" exact="DENV" post="E protein, may also be associated with neurovirulence (Kostyuchenko"/>
  <result pre="changed structurally when the virus was incubated at 37°C, whereas" exact="ZIKV" post="virus particles remained structurally stable, most likely due to"/>
  <result pre="likely due to the tightly packed and complex interactions of" exact="ZIKV" post="E dimers. The ability of ZIKV to survive harsh"/>
  <result pre="and complex interactions of ZIKV E dimers. The ability of" exact="ZIKV" post="to survive harsh conditions may explain why the virus"/>
  <result pre="prM amino acid substitutions to E protein thermostability and consequent" exact="ZIKV" post="structural biology are not yet well known. However, changes"/>
  <result pre="be empirically tested. Perspectives for the Use of prM in" exact="ZIKV" post="Vaccine Development The ZIKV viral envelope is comprised of"/>
  <result pre="for the Use of prM in ZIKV Vaccine Development The" exact="ZIKV" post="viral envelope is comprised of two viral proteins, the"/>
  <result pre="have become major targets of vaccine design and development against" exact="ZIKV" post="infections (Table 2) (WHO, 2018). These structural proteins have"/>
  <result pre="been targeted because they are: (i) non-replicating subunits of the" exact="ZIKV" post="genome so they present a safer candidate profile for"/>
  <result pre="Grifoni et al., 2017; Goo et al., 2018). Table 2" exact="ZIKV" post="vaccine candidates undergoing clinical trialsa. Sponsor/Developer Platform Immunogen Adjuvant"/>
  <result pre="trials according to the World Health Organization (WHO, 2018). The" exact="ZIKV" post="vaccines currently under development are mainly based on purified"/>
  <result pre="al., 2018; Modjarrad et al., 2018). Importantly, none of these" exact="ZIKV" post="vaccine approaches have achieved success in terms of generating"/>
  <result pre="vaccine could provide complete protection in mice against challenge with" exact="ZIKV" post="strains linked to major clinical complications. That study also"/>
  <result pre="protection, evidencing the important role of prM protein in enhancing" exact="ZIKV" post="immunogenicity. The ZIKV prM-E DNA vaccine resulted in a"/>
  <result pre="important role of prM protein in enhancing ZIKV immunogenicity. The" exact="ZIKV" post="prM-E DNA vaccine resulted in a higher titer of"/>
  <result pre="phenomenon has also been reported in another study using a" exact="ZIKV" post="prM-E immunogen as a vaccine candidate (Yi et al.,"/>
  <result pre="This outcome may be due to the structural nature of" exact="ZIKV" post="E protein as it is the main viral protein"/>
  <result pre="has also shown the ability to confer full protection against" exact="ZIKV" post="challenge in humanized DRAG mice that have robust antibody"/>
  <result pre="vaccine produced by immunizing mice with VLPs that incorporates full-length" exact="ZIKV" post="structural proteins (C-prM-E) can also endow full protection against"/>
  <result pre="ZIKV structural proteins (C-prM-E) can also endow full protection against" exact="ZIKV" post="and induces production of more ZIKV-neutralizing antibodies than DNA"/>
  <result pre="than DNA vaccines (Garg et al., 2017). A chimeric live-attenuated" exact="ZIKV" post="prM-E vaccine candidate, using a commercialized JEV vaccine as"/>
  <result pre="prM-E was replaced with the corresponding prM-E from an Asian" exact="ZIKV" post="strain. Another approach using chimeric ZIKV with DENV prM-E"/>
  <result pre="prM-E from an Asian ZIKV strain. Another approach using chimeric" exact="ZIKV" post="with DENV prM-E proteins or a chimeric DENV with"/>
  <result pre="an Asian ZIKV strain. Another approach using chimeric ZIKV with" exact="DENV" post="prM-E proteins or a chimeric DENV with ZIKV prM-E"/>
  <result pre="using chimeric ZIKV with DENV prM-E proteins or a chimeric" exact="DENV" post="with ZIKV prM-E proteins revealed robust protection in immunized"/>
  <result pre="ZIKV with DENV prM-E proteins or a chimeric DENV with" exact="ZIKV" post="prM-E proteins revealed robust protection in immunized mice through"/>
  <result pre="2017). This vaccine uses an RNA replicon vector to package" exact="ZIKV" post="prM-E protein for expression in BHK21 cells. Protein expression"/>
  <result pre="dendrimer nanoparticle (MDNP) RNA vaccine. Modified mRNA vaccines based on" exact="ZIKV" post="prM-E proteins have also been developed (Pardi et al.,"/>
  <result pre="by the host innate immune system. The modified mRNAs encoding" exact="ZIKV" post="prM-E proteins are then encapsulated in lipid nanoparticles for"/>
  <result pre="SVPs that can induce production of neutralizing antibodies. These modified" exact="ZIKV" post="mRNA vaccines use non-self-amplifying mRNA that cannot integrate into"/>
  <result pre="These mRNA vaccines have exhibited robust immunization and protection against" exact="ZIKV" post="infection in both immunocompromised AG129 and C56BL/6 mice. ZIKV"/>
  <result pre="against ZIKV infection in both immunocompromised AG129 and C56BL/6 mice." exact="ZIKV" post="mRNA vaccine concepts are currently undergoing clinical trials and"/>
  <result pre="to be an important milestone in combating current and future" exact="ZIKV" post="outbreaks. Concluding Remarks Zika virus has become a major"/>
  <result pre="milestone in combating current and future ZIKV outbreaks. Concluding Remarks" exact="Zika" post="virus has become a major public health concern, with"/>
  <result pre="and purifying selection pressures might have facilitated modifications of the" exact="ZIKV" post="genome that enhance its replication efficiency and reduce host"/>
  <result pre="has been linked to increased neurovirulence, suggesting that alterations of" exact="ZIKV" post="prM protein may enhance viral virulence. Further studies on"/>
  <result pre="efficiency. Various platforms have been employed to generate vaccines against" exact="ZIKV" post="infections, including purified inactivated virus, plasmid DNA, and mRNA"/>
  <result pre="and E proteins are utilized. In contrast, sole use of" exact="ZIKV" post="prM protein in vaccines against ZIKV has not yet"/>
  <result pre="contrast, sole use of ZIKV prM protein in vaccines against" exact="ZIKV" post="has not yet proven as effective as prM-E combinations."/>
  <result pre="more likely to result in another epidemic. Furthermore, whether the" exact="ZIKV" post="vaccines currently under development can be effective against future"/>
  <result pre="Additional focused studies on the molecular and structural biology of" exact="ZIKV" post="prM may accelerate our ability to tackle this emerging"/>
  <result pre="Trop. Med. Hyg77149–151. 10.1016/0035-9203(83)90053-66306872 AtkinsonB.HearnP.AfroughB.LumleyS.CarterD.AaronsE. J.et al. (2016). Detection of" exact="Zika" post="virus in Semen.Emerg. Infect. Dis22:940. 10.3201/eid2205.16010727088817 BosS.ViranaickenW.TurpinJ.El-KalamouniC.RocheM.Krejbich-TrototP.et al. (2018)."/>
  <result pre="(2018). The structural proteins of epidemic and historical strains of" exact="Zika" post="virus differ in their ability to initiate viral infection"/>
  <result pre="W.KhanO. F.LingJ.AndersonD. G.et al. (2017). An RNA nanoparticle vaccine against" exact="Zika" post="virus elicits antibody and CD8+ T cell responses in"/>
  <result pre="and potential.Ann. N. Y. Acad. Sci.951272–285. 10.1111/j.1749-6632.2001.tb02703.x11797784 CounotteM.Egli-GanyD.RiesenM.AbrahaM.PorgoT.WangJ.et al. (2018)." exact="Zika" post="virus infection as a cause of congenital brain abnormalities"/>
  <result pre="peer review]. DaiL.SongJ.LuX.DengY. Q.MusyokiA. M.ChengH.et al. (2016). Structures of the" exact="Zika" post="virus envelope protein and its complex with a flavivirus"/>
  <result pre="human T and B cells.PLoS One6:e19826. 10.1371/journal.pone.001982621611197 DickG. W. (1952)." exact="Zika" post="virus. II. Pathogenicity and physical properties.Trans. R. Soc. Trop."/>
  <result pre="Soc. Trop. Med. Hyg.46521–534. 10.1016/0035-9203(52)90043-612995441 DickG. W.KitchenS. F.HaddowA. J. (1952)." exact="Zika" post="virus. I. Isolations and serological specificity.Trans. R. Soc. Trop."/>
  <result pre="10.1016/0035-9203(52)90042-412995440 DuffyM. R.ChenT. H.HancockW. T.PowersA. M.KoolJ. L.LanciottiR. S.et al. (2009)." exact="Zika" post="virus outbreak on Yap Island, Federated States of Micronesia.N."/>
  <result pre="Engl. J. Med.3602536–2543. 10.1056/NEJMoa080571519516034 collab: ECDC (2014). Rapid risk assessment:" exact="Zika" post="virus Infection Outbreak, French Polynesia. Available at: https://ecdc.europa.eu/en/publications-data/rapid-risk-assessment-zika-virus-infection-outbreak-french-polynesia#no-link [accessed"/>
  <result pre="2018]. FayeO.FreireC. C.IamarinoA.FayeO.de OliveiraJ. V.DialloM.et al. (2014). Molecular evolution of" exact="Zika" post="virus during its emergence in the 20(th) century.PLoS Negl."/>
  <result pre="B.JoshiA. (2017). Development of virus-like-particle vaccine and reporter assay for" exact="Zika" post="virus.J. Virol.91: e00834-17. 10.1128/jvi.00834-1728794019 GaudinskiM. R.HouserK. V.MorabitoK. M.HuZ.YamshchikovG.RothwellR. S.et"/>
  <result pre="M.HuZ.YamshchikovG.RothwellR. S.et al. (2018). Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
  <result pre="10.1016/s0140-6736(17)33105-729217376 GooL.DeMasoC. R.PelcR. S.LedgerwoodJ. E.GrahamB. S.KuhnR. J.et al. (2018). The" exact="Zika" post="virus envelope protein glycan loop regulates virion antigenicity.Virology515191–202. 10.1016/j.virol.2017.12.03229304471"/>
  <result pre="loop regulates virion antigenicity.Virology515191–202. 10.1016/j.virol.2017.12.03229304471 GourinatA. C.O’ConnorO.CalvezE.GoarantC.Dupont-RouzeyrolM. (2015). Detection of" exact="Zika" post="virus in urine.Emerg. Infect. Dis.2184–86. 10.3201/eid2101.14089425530324 GrifoniA.PhamJ.SidneyJ.O’RourkeP. H.PaulS.PetersB.et al."/>
  <result pre="(2017). Prior dengue virus exposure shapes T cell immunity to" exact="Zika" post="virus in humans.J. Virol.10.1128/jvi.01469-17 [Epub ahead of print]. 28978707"/>
  <result pre="humans.J. Virol.10.1128/jvi.01469-17 [Epub ahead of print]. 28978707 HennesseyM.FischerM.StaplesJ. E. (2016)." exact="Zika" post="virus spreads to new areas – Region of the"/>
  <result pre="2016.MMWR Morb. Mortal. Wkly. Rep.6555–58. 10.15585/mmwr.mm6503e126820163 KauffmanE. B.KramerL. D. (2017)." exact="Zika" post="virus mosquito vectors: competence, biology, and vector control.J. Infect."/>
  <result pre="X.ZhangS.FibriansahG.NgT. S.OoiJ. S.et al. (2016). Structure of the thermally stable" exact="Zika" post="virus.Nature533425–428. 10.1038/nature1799427093288 KrauerF.RiesenM.ReveizL.OladapoO. T.Martinez-VegaR.PorgoT.V.et al. (2017). Zika virus infection"/>
  <result pre="the thermally stable Zika virus.Nature533425–428. 10.1038/nature1799427093288 KrauerF.RiesenM.ReveizL.OladapoO. T.Martinez-VegaR.PorgoT.V.et al. (2017)." exact="Zika" post="virus infection as a cause of congenital brain abnormalities"/>
  <result pre="guillain-barre syndrome: systematic review.PLoS Med.14:e1002203. 10.1371/journal.pmed.100220328045901 KwongJ. C.DruceJ. D.LederK. (2013)." exact="Zika" post="virus infection acquired during brief travel to Indonesia.Am. J."/>
  <result pre="LaroccaR. A.AbbinkP.PeronJ. P.ZanottoP. M.IampietroM. J.Badamchi-ZadehA.et al. (2016). Vaccine protection against" exact="Zika" post="virus from Brazil.Nature536474–478. 10.1038/nature1895227355570 LazearH. M.GoveroJ.SmithA. M.PlattD. J.FernandezE.MinerJ. J.et"/>
  <result pre="M.GoveroJ.SmithA. M.PlattD. J.FernandezE.MinerJ. J.et al. (2016). A mouse model of" exact="Zika" post="virus pathogenesis.Cell Host Microbe19720–730. 10.1016/j.chom.2016.03.01027066744 LiL.LokS. M.YuI. M.ZhangY.KuhnR. J.ChenJ.et"/>
  <result pre="L.WangH. J.HuangX. Y.QiuY. F.JiX.et al. (2018). Development of a chimeric" exact="Zika" post="vaccine using a licensed live-attenuated flavivirus vaccine as backbone.Nat."/>
  <result pre="as backbone.Nat. Commun.9:673. 10.1038/s41467-018-02975-w29445153 LinH. H.YipB. S.HuangL. M.WuS. C. (2018)." exact="Zika" post="virus structural biology and progress in vaccine development.Biotechnol. Adv.3647–53."/>
  <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
  <result pre="placebo-controlled clinical trials.Lancet391563–571. 10.1016/s0140-6736(17)33106-929217375 MussoD.RocheC.NhanT. X.RobinE.TeissierA.Cao-LormeauV. M. (2015). Detection of" exact="Zika" post="virus in saliva.J. Clin. Virol.6853–55. 10.1016/j.jcv.2015.04.02126071336 OehlerE.WatrinL.LarreP.Leparc-GoffartI.LastereS.ValourF.et al. (2014)."/>
  <result pre="Zika virus in saliva.J. Clin. Virol.6853–55. 10.1016/j.jcv.2015.04.02126071336 OehlerE.WatrinL.LarreP.Leparc-GoffartI.LastereS.ValourF.et al. (2014)." exact="Zika" post="virus infection complicated by Guillain-Barre syndrome–case report, French Polynesia,"/>
  <result pre="Aided Mol. Des.311009–1019. 10.1007/s10822-017-0076-829064083 PardiN.HoganM. J.PelcR. S.MuramatsuH.AndersenH.DeMasoC. R.et al. (2017)." exact="Zika" post="virus protection by a single low-dose nucleoside-modified mRNA vaccination.Nature543248–251."/>
  <result pre="of protein evolution in the genome of pre-epidemic and epidemic" exact="Zika" post="virus.Infect. Genet. Evol.5174–85. 10.1016/j.meegid.2017.03.01228315476 RichnerJ. M.HimansuS.DowdK. A.ButlerS. L.SalazarV.FoxJ. M.et"/>
  <result pre="G.et al. (2016). The 3.8 A resolution cryo-EM structure of" exact="Zika" post="virus.Science352467–470. 10.1126/science.aaf531627033547 SmithburnK. C. (1952). Neutralizing antibodies against certain"/>
  <result pre="in East Africa.J. Immunol.69223–234. 14946416 SongB. H.YunS. I.WoolleyM.LeeY. M. (2017)." exact="Zika" post="virus: history, epidemiology, transmission, and clinical presentation.J. Neuroimmunol.30850–64. 10.1016/j.jneuroim.2017.03.00128285789"/>
  <result pre="G.WuA.OuyangS.LiC.BrasilP.et al. (2016). From mosquitos to humans: genetic evolution of" exact="Zika" post="Virus.Cell Host Microbe19561–565. 10.1016/j.chom.2016.04.00627091703 WetsmanN. (2017). The missing pieces:"/>
  <result pre="Host Microbe19561–565. 10.1016/j.chom.2016.04.00627091703 WetsmanN. (2017). The missing pieces: Lack of" exact="Zika" post="data from Africa complicates search for answers.Nat. Med.23904–906. 10.1038/nm0817-90428777794"/>
  <result pre="the International Health Regulations (2005) (IHR 2005) Emergency Committee on" exact="Zika" post="virus and Observed Increase in Neurological Disorders and Neonatal"/>
  <result pre="Available at: http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/ [Accessed 11 May, 2018]. WuY.LiuQ.ZhouJ.XieW.ChenC.WangZ.et al. (2017)." exact="Zika" post="virus evades interferon-mediated antiviral response through the co-operation of"/>
  <result pre="in vitro.Cell Discov.3:17006. 10.1038/celldisc.2017.628417013 XieX.YangY.MuruatoA. E.ZouJ.ShanC.NunesB. T.et al. (2017). Understanding" exact="Zika" post="virus stability and developing a chimeric vaccine through functional"/>
  <result pre="al. (2017). A DNA vaccine protects human immune cells against" exact="Zika" post="virus infection in humanized mice.EBioMedicine2587–94. 10.1016/j.ebiom.2017.10.00629033368 YoshiiK.IgarashiM.IchiiO.YokozawaK.ItoK.KariwaH.et al. (2012)."/>
  <result pre="al. (2017). A single mutation in the prM protein of" exact="Zika" post="virus contributes to fetal microcephaly.Science358933–936. 10.1126/science.aam712028971967 ZanlucaC.Dos SantosC. N."/>
  <result pre="virus contributes to fetal microcephaly.Science358933–936. 10.1126/science.aam712028971967 ZanlucaC.Dos SantosC. N. (2016)." exact="Zika" post="virus – an overview.Microbes Infect.18295–301. 10.1016/j.micinf.2016.03.00326993028 ZhuZ.ChanJ. F.TeeK. M.ChoiG."/>
  <result pre="C.et al. (2016). Comparative genomic analysis of pre-epidemic and epidemic" exact="Zika" post="virus strains for virological factors potentially associated with the"/>
 </snippets>
</snippetsTree>
